Twice a financial year, NHS England makes decisions on which new specialised treatments should be routinely commissioned. The decisions are based on advice from the Clinical Priorities Advisory Group (CPAG), which is made up of doctors, health experts, and patient representatives, and taken by the NHS England Board.

Treatments are grouped into five levels of priority, with those that have the highest relative clinical benefit for patients and the lowest relative cost classified as level one, and treatments with the lowest relative clinical benefit and highest relative cost classified as level five.

The CPAG ranking of treatments considered in the May 2021 prioritisation round is set out in this document.